HEC
VIVO

Hudson Executive Capital’s Meridian Bioscience Inc VIVO Stock Holding History

Hudson Executive Capital’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-123,300
Closed -$1.94M – 7
2017
Q2 		$1.94M Buy
+123,300
New +$1.78M 0.89% 7

Other funds holding VIVO

BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hudson Executive Capital's VIVO Position: Q3 2017 in Review

Hudson Executive Capital sold out of Meridian Bioscience Inc (VIVO) in Q3 2017, closing a stake of 123,300 shares — an estimated $1.94M sold.

Hudson Executive Capital first reported a position in VIVO in Q2 2017 and held it in 1 quarter. The position peaked at $1.94M in Q2 2017. 172 funds tracked by Wall St. Rank hold VIVO as of Q3 2017.

  • Hudson Executive Capital reported no remaining Meridian Bioscience Inc position as of Q3 2017 after selling out during the quarter.
  • Hudson Executive Capital sold 123,300 Meridian Bioscience Inc shares in Q3 2017, an estimated $1.94M.
  • Hudson Executive Capital first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 1 quarter.
  • Hudson Executive Capital's Meridian Bioscience Inc position peaked at $1.94M in Q2 2017.
  • 172 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2017.

Based on Hudson Executive Capital's 13F filing for Q3 2017, filed 14 Nov 2017.